

1. **Ensoli B.**, and Cafaro A. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine. J. Biol. Regul. and Homeost. Agents 14:22-26, 2000.
2. Annunziato F., Galli G., Nappi F., Cosmi L., Manetti R., Maggi E., **Ensoli B.** and Romagnani S. Limited expression of R5-tropic HIV-1 in CCR-5 positive type 1-polarized T cells explained by their ability to reproduce RANTES, MIP-1 α and MIP-1 β . Blood 95:1167-1174, 2000.
3. Rezza G., Befeuka Tchangmena O., Andreoni M., Bugarini R., Toma L., Kaou Bakary D., Glikoutou M., Sarmati L., Monini P., Pezzotti P., and **Ensoli B.** Prevalence and risk factors for Human Herpesvirus 8 infection in Northern Cameroon. Sexually Transmitted Diseases 27:159-164, 2000.
4. Rezza G., Dorrucchi M., Serraino D., Andreoni M., Giuliani M., Zerboni R., Sarmati L., Colangeli V., Salassa B., Monini P., **Ensoli B.**, and Pezzotti P. for the Italian Seroconversion Study. Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. AIDS 14:1647-1653, 2000.
5. Sgadari C., Toschi E., Palladino C., Barillari G., Carlei D., Cereseto A., Ciccolella C., Yarchoan R., Monini P., Stürzl M., and **Ensoli B.** Mechanism of Paclitaxel activity in Kaposi's sarcoma. J. Immunol. 165:509-517, 2000.
6. Borsetti A., Parolin C., Ridolfi B., Sernicola L., Geraci A., **Ensoli B.**, and Titti F. CD4-independent infection of two CD4⁺/CCR5⁻/CXCR4⁺ pre-T-cell lines by human and simian immunodeficiency viruses. J. Virol. 74:6689-6894, 2000.
7. Clerici M., Buttò S., Lukwiya M., Saresella M., Declich S., Trabattoni D., Pastori C., Piconi S., Fracasso C., Fabiani M., Ferrante P., Rizzardini G., and Lopalco L. for the Italian-Ugandan AIDS Project (Accorsi S., Amet O.A., Arienti D., Awil P.O., Barassi C., Benon B., Biasin M., Cogliati M., Colombo F., Corti P., Cristofaro A., **Ensoli B.**, Fossati S., Fusi M.L., Greco D., Jacob O., Milazzo F., Ranghiasi A., Rosolen T., Villa M.L., Tancredi P., Zagliani A.). Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 14:2083-2092, 2000.
8. **Ensoli B.**, and Buttò S. The development of a vaccine against AIDS based on the HIV-1 Tat protein. South African Journal of Science 96:324-327, 2000.
9. Cafaro A., Caputo A., Maggiorella M.T., Baroncelli S., Fracasso C., Pace M., Borsetti A., Sernicola L., Negri D.R.M., Ten Haaf P., Betti M., Michelini Z., Macchia I., Fanales-Belasio E., Belli R., Corrias F., Buttò S., Verani P., Titti F., and **Ensoli B.** SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol 29: 193-208, 2000.
10. Ridolfi B., Parolin C., Sernicola L., Fulgenzi D., Geraci A., **Ensoli B.**, Titti F., and Borsetti A. Susceptibility of two CD4⁻ T cell lines to HIV and SIV infection. The Fifth European Conference on Experimental AIDS Research (ECEAR), Madrid (Spain), June 16-19, pp. 113-119, 2000.
11. Tinari A., Monini P., Marchetti M., Ammendolia M.G., Leone P., **Ensoli B.**, and Superti F. Lytic growth of human herpesvirus 8: morphological aspects. Ultrastructural Pathology 24:301-310, 2000.

12. **Ensoli B.**, Nappi F., and Buttò S. Meccanismo di infezione dei virus dell'immunodeficienza acquisita (HIV-1, HIV-2, SIV). Enciclopedia Medica Italiana "Retrovirus", Aggiornamento II, Tomo III, pp. 5085-5089, 2000.
13. **Ensoli B.**, Stürzl M., and Monini P. Cytochine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. Sem. Cancer Biol., 10:367-381, 2000.
14. **Ensoli B.**, Monini P., and Sgadari C. Pathogenesis of Kaposi's sarcoma (KS): new insights in KS treatment. In: Anlaids Notizie (Speciale), Anno 10, Supplemento al n. 6, Dicembre 2000, pp. 28-38.
15. **Ensoli B.**, and Cafaro A. Novel strategies toward the development of an effective vaccine to prevent Human Immunodeficiency Virus infection or Acquired Immunodeficiency Virus. In: AIDS Clinical Review 2000/2001, Volberding and Jacobson Eds., pp. 23-61.
16. Barillari G., Albonici L., Incerpi F., Bogetto L., Pistrutto G., Volpi A., **Ensoli B.**, and Manzari V. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing $\alpha 5\beta 1$ integrin expression and function. Atherosclerosis, 154:377-385, 2001.
17. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., Goletti D., Borsetti A., Pace M., Fanales-Belasio E., Ridolfi B., Negri D.R.M., Sernicola L., Belli R., Corrias F., Macchia I., Leone P., Michelini Z., ten Haaf P., Buttò S., Verani P., and **Ensoli B.** Vaccination with DNA containing *tat* coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine, 19:2862-2877, 2001.
18. Bussolino F., Mitola S., Serini G., Barillari G., and **Ensoli B.** Interactions between endothelial cells and HIV-1. Int. J. Biochem. Cell Biol., 33:371-390, 2001.
19. Betti M., Voltan R., Marchisio M., Mantovani I., Boarini C., Nappi F., **Ensoli B.**, and Caputo A. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. Vaccine, 19:3408-3419, 2001.
20. Laus M., Sparnacci K., **Ensoli B.**, Buttò S., Caputo A., Mantovani I., Zuccheri G., Samori B., and Tondelli L. Complex associates of plasmid DNA and a novel class of block Copolymers with PEG and cationic segments as new vectors for gene delivery. J. Biomater. Sci. Polym. Ed., 12:209-228, 2001.
21. **Ensoli B.**, Stürzl M., and Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv. Cancer Res., 81:161-200, 2001.
22. **Ensoli B.**, Sgadari C., Barillari G., Sirianni M.C., Stürzl M., and Monini P. Biology of Kaposi's Sarcoma. Eur. J. Cancer, 37:1251-1269, 2001.
23. Stürzl M., Zietz C., Monini P., and **Ensoli B.** Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multi-step concept of tumorigenesis. Adv. Cancer Res., 81:125-159, 2001.
24. Rimessi P., Bonaccorsi A., Stürzl M., Fabris M., Brocca-Cofano E., Caputo A., Melucci-Vigo G., Falchi M., Cafaro A., Cassai E., **Ensoli B.**, and Monini P. Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma. J. Virol., 75:7161-7174, 2001.

25. Accorsi S., Fabiani M., Lukwija M., Onek P.A., Di Mattei P., Declich S. for the Italian-Ugandan AIDS Cooperation Program (Greco D., Dente M.G., Tancredi P., Ranghiasi A., Corti P., Corrado B., Onyut A., Ouma J., Hasman A., Biryahwabo B., Rosolen T., **Ensoli B.**, Buttò S., Clerici M., Zagliani A., Rizzardini G., Milazzo F., Piconi S., Ferrante P., Saresella M., Aloï A., Cosulich A). The increasing burden of infectious diseases on hospital services at St. Mary's Hospital Lacor, Gulu, Uganda. Am. J. Trop. Med. Hyg., 64:154-158, 2001.
26. Ascherl G., Sgadari C., Bugarini R., Bogner J., Schatz O., **Ensoli B.**, and Stürzl M. Serum concentrations of fibroblast growth factor-2 are increased in HIV type 1-infected patients and inversely related with survival probability. AIDS Res. Hum. Retrov., 17:1035-1039, 2001.
27. Schatz O., Monini P., Bugarini R., Neipel F., Schulz T.F., Andreoni M., Erb P., Eggers M., Haas J., Buttò S., Lukwiya M., Bogner J.R., Yaguboglu S., Sheldon J., Sarmati L., Goebel F. D., Hintermaier R., Enders G., Regamey N., Wernli M., Stürzl M., Rezza G., and **Ensoli B.** Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J. Med. Virol. 65:123-132, 2001.
28. Ten Haaft P., Almond N., Biberfeld G., Cafaro A., Cranage M., **Ensoli B.**, Hunsmann G., Polyanskaya N., Stahl-Hennig C., Thortensson R., Titti F., Heeney J. Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J. Med. Primatol. 30:207-214, 2001.
29. Sirianni M.C., Libi F., Scaramuzzi D., Topino S., Campagna M., Colbacchi B., Novi A., De Cristofaro M.R., Fiorelli V., Ensoli F., and **Ensoli B.** Modulation of the natural killer cell activity of peripheral blood mononuclear cells by the HIV Tat protein. Proceedings of the 6th European Conference on Experimental AIDS Research (ECEAR 2001), Edinburgh (Scotland), June 23-26, 2001, pp.81-85.
30. Toschi E., Barillari G., Sgadari C., Bacigalupo I., Cereseto A., Carlei D., Palladino C., Zietz C., Leone P., Stürzl M., Buttò S., Cafaro A., Monini P., and **Ensoli B.** Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability in vivo by the Human Immunodeficiency Virus-1 Tat protein and Basic Fibroblast Growth Factor. Mol. Biol. Cell, 12:2934-2946, 2001.
31. Guenzi E., Töpolt K., Cornali E., Lubeseder-Martellato C., Zietz C., Kremmer E., Nappi F., Schwemmler M., Hohenadl C., Jörg A., Matzen K., Barillari G., Tschachler E., Monini P., **Ensoli B.**, and Stürzl M. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J., 20:5568-5577, 2001.
32. Monini P., Sirianni M.C., Franco M., Vincenzi L., Topino S., Goletti D., Leone P., Leone P., Chiozzini C., Nicastrì E., Andreoni M., Borduagni O., Sgadari C., Rezza G., Stürzl M., and **Ensoli B.** Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. Clin. Infect. Dis., 33:1782-1785, 2001.
33. De Maria A., Biassoni R., Fogli M., Rizzi M., Cantoni C., Costa P., Conte R., Mavilio D., **Ensoli B.**, Cafaro A., Moretta A., Moretta L. Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca Fascicularis NK cells. Eur. J. Immunol., 31:3546-3556, 2001.

34. Rezza G., Danaya R.T., Wagner T.M., Sarmati L., Owen I.L., Monini P., Andreoni M., Suligoi B.S., **Ensoli B.**, and Pozio E. Human Herpesvirus-8 and Other Viral Infections, Papua New Guinea. Emerg. Infect. Dis. 7:893-895, 2001.
35. Andreoni M., Goletti D., Pezzotti P., Pozzetto A., Monini P., Sarmati L., Farchi F., Tisone G., Piazza A., Pisani F., Angelico M., Leone P., Citterio F., **Ensoli B.**, Rezza G. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's Sarcoma in renal and liver transplant recipients. J. Infect. 43:195-199, 2001.
36. Serraino D., Toma L., Andreoni M., Buttò S., Tchangmena O., Sarmati L., Monini P., Franceschi S., **Ensoli B.**, and Rezza G. A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. Eur. J. Epidemiol. 17:871-876, 2001.
37. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., and **Ensoli B.** Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function and antigen-specific T cell responses. J. Immunol., 168:197-206, 2002.
38. Battistini A., Marsili G., Sgarbanti M., **Ensoli B.**, and Hiscott J. Review: IRF Regulation of HIV-1 Long Terminal Repeat Activity. J. Interferon Cytokine Res. 22:27-37, 2002.
39. Sgadari C., Barillari G., Toschi E., Carlei D., Bacigalupo I., Baccarini S., Palladino C., Leone P., Bugarini R., Malavasi L., Cafaro A., Falchi M., Valdembrì D., Rezza G., Bussolino F., Monini P., and **Ensoli B.** HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat. Med., 8:225-232, 2002.
40. **Ensoli B.**, and Cafaro A. HIV-1 Tat vaccines. Virus Res., 82(1-2):91-101, 2002.
41. Barillari G., and **Ensoli B.** Angiogenic Effects of Extracellular Human Immunodeficiency virus type 1 Tat Protein and its role in the pathogenesis of AIDS-associated Kaposi's Sarcoma. Clin. Microbiol. Rev., 15:310-32, 2002.
42. **Ensoli B.** HIV protease inhibitors have specific anti-cancer effects. Biomed. & Pharmacother., Vol. 56, No. 8, 2002.
43. Caputo A., Betti M., Altavilla G., Bonaccorsi A., Boarini C., Marchisio M., Buttò S., Sparnacci K., Laus M., Tondelli L., and **Ensoli B.** Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 *tat* DNA for vaccine application. Vaccine, 20:2303-2317, 2002.
44. Sgarbanti M., Borsetti A., Moscufo N., Bellocchi M.C., Ridolfi B., Nappi F., Marsili G., Marziali G., Coccia E.M., **Ensoli B.**, and Battistini A. Modulation of HIV-1 Replication by Interferon Regulatory Factors. J. Exp. Med., 195:1359-1370, 2002.
45. Almond N., Anzala O., Bektimirov T., Berman P., Birx D., Carvalheiro J., Chongprasert S., Cichutek K., Darbyshire J., Duarte C., **Ensoli B.**, Fenyo E.M., Girard M., Goldenthal K., Golding H., Holmes H., Johnston M., Mallet L., Mawle A., Mugerwa R., Pitisuttithum P., Rees H., Robertson J., Rowland-Jones S., Sang G., Schild G., Shao Y., Sheets R., Takemori T., Tramont E., Vandepapeliere P., van der Groen G., Weiner D., and Widdus R. Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines. (Collective views of an international group of experts, Report from a WHO-UNAIDS

Consultation, Geneva, Switzerland, March 13-15, 2001); AIDS, 16:W15-W25, 2002.

46. Micheletti F., Monini P., Fortini C., Rimessi P., Bazzaro M, Andreoni M., Giuliani M., Traniello S., **Ensoli B.**, and Gavioli R. Identification of cytotoxic T lymphocyte epitopes of human herpes virus 8. Immunology, 106:395-403, 2002.
47. Sirianni M.C., Libi F., Scaramuzzi D., Campagna M., Monini P., and **Ensoli B.** NK cell activity, HHV-8 infection and HAART. In Monduzzi Eds., International Proceedings Division, XIV International AIDS Conference, Barcelona (Spain), July 7 – July 12, 2002, pp. 39-41.
48. Cara A., Cafaro A., Baroncelli S., Maggiorella M.T., Negri D.R.M., Fanales-Belasio E., Moretti S., Michelini Z., Fiorelli V., Buttò S., Tripiciano A., Sernicola L., Scoglio A., Borsetti A., Ridolfi B., Macchia I., Mancini M.G., Belli R., Farcomeni S., Nappi F., Vardas E., Colvin M., Laguardia E., Caputo A., Magnani M., Titti F., and **Ensoli B.** Development of HIV/AIDS vaccine based on Tat: preclinical and clinical studies. In Monduzzi Eds., International Proceedings Division, XIV International AIDS Conference, Barcelona (Spain), July 7 – July 12, 2002, pp. 251-256.
49. Fanales-Belasio E., Cafaro A., Cara A., Negri D.R.M., Fiorelli V., Buttò S., Moretti S., Maggiorella M.T., Baroncelli S., Michelini Z., Tripiciano A., Sernicola L., Scoglio A., Borsetti A., Ridolfi B., Bona R., ten Haaf P., Macchia I., Leone P., Pavone-Cossut M. R., Nappi F., Vardas E., Magnani M., Laguardia E., Caputo A., Titti F., and **Ensoli B.** HIV-1 Tat-Based Vaccines: from Basic Science to Clinical Trials. DNA and Cell Biol., 21:599-610, 2002.
50. Sirianni M.C., Vincenti L., Topino S., Giovanetti A., Mazzetta F., Libi F., Scaramuzzi D., Andreoni M., Pinter E., Baccarini S., Rezza R., Monini P., and **Ensoli B.** NK cell activity controls human herpesvirus 8 latent infection and is restored upon HAART in AIDS patients with regressing Kaposi's sarcoma. Eur. J. Immunol., 32:2711-2720, 2002.
51. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., **Ensoli B.**, Mühradt P.F., and Guzman C.A. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol., 32:2857-2865, 2002.
52. **Ensoli B.** Gli inibitori delle proteasi di HIV hanno una potente azione anti-angiogenica ed anti-tumorale indipendente dalla loro attività anti-retrovirale. In: Indinavir nella strategia terapeutica della malattia da HIV, Edizioni Internazionali srl, Divisione EDIMES-Edizioni Medico-Scientifiche 2002, pp.59-78.
53. Lubeseder-Martellato C., Guenzi E., Jörg A., Töpolt K., Naschberger E., Kremmer E., Zietz C., Tschachler E., Hutzler P., Schwemmler M., Matzen K., Grimm T., **Ensoli B.**, and Stürzl M. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am. J. Pathol. 161:1749-1759, 2002.
54. Toschi E., Sgadari C., Monini P., Barillari G., Bacigalupo I., Palladino C., Baccarini S., Carlei D., Grosso G., Sirianni M.C. and **Ensoli B.** Treatment of Kaposi's Sarcoma, an update. Anti-Cancer Drugs, 13:977-987, 2002.

55. Monini P., Sirianni M.C., and **Ensoli B.** Concomitant clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma upon α -interferon therapy. Oncol. Rev. J., issue 4, pp.18-20, 2002.
56. Broccolo F., Locatelli G., Sarmati L., Piergiovanni S., Veglia F., Andreoni M., Buttò S., **Ensoli B.**, Lusso P., Malnati M.S. Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. J. Clin. Microbiol. 40:4652-4658, 2002.
57. Sgadari C., Monini P., Toschi E., Baccarini S., Grosso M.G., Moracci G., Malavasi L., and **Ensoli B.** HIV Protease Inhibitors inhibit Kaposi's sarcoma by blocking angiogenesis and tumour cell invasion. Haematologica, (Meeting Supplement 1 to n. 11) 87:37-41, 2002.
58. Grosso G., Sgadari C., Barillari G., Toschi E., Bacigalupo I., Carlei D., Palladino C., Baccarini S., Malavasi L., Moracci G., Leone P., Chiozzini C., Monini P., and **Ensoli B.** Trattamento del Sarcoma di Kaposi mediante gli inibitori della proteasi di HIV. Recenti Progressi in Medicina (Italian), Vol. 94, n. 2, pp.69-74, 2003.
59. Caputo A., Gavioli R., Altavilla G., Brocca Cofano E., Boarini C., Betti M., Castaldello A., Lorenzini F., Micheletti F., Cafaro A., Sparnacci K., Laus M., Tondelli L., and **Ensoli B.** Immunization with low doses of HIV-1 *tat* DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine, 21: 1103-1111, 2003.
60. Monini P., Sgadari C., Barillari G. and **Ensoli B.** The HIV protease inhibitors: anti-retroviral agents with anti-inflammatory, anti-angiogenic and anti-tumor activity. J. Antimicrobial Chemother., 51:207-211, 2003.
61. Dominici S., Laguardia M.E., Serafini G., Chiarantini L., Fortini C., Tripiciano A., Brocca-Cofano E., Scoglio A., Caputo A., Fiorelli V., Gavioli R., Cafaro A., **Ensoli B.**, and Magnani M. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. Vaccine, 21:2082-2090, 2003.
62. **Ensoli B.**, Sgadari C., Barillari G. and Monini P. The Fibroblast Growth Factors. In: The Cytokine Handbook (IV Edition, Chapter 31, Thomson A. and Lotze M. Eds.), Vol. II, pp.747-781, 2003.
63. Borsutzky S., Fiorelli V., Ebensen T., Tripiciano A., Rharbaoui F., Scoglio A., Link C., Nappi F., Morr M., Buttò S., Cafaro A., Mühlradt P.F., **Ensoli B.**, and Guzman CA. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol., 33:1548-1556, 2003.
64. Marinaro M., Riccomi A., Rappuoli R., Pizza M., Fiorelli V., Tripiciano A., Cafaro A., **Ensoli B.**, and De Magistris M.T. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine, 21(25-26)-3503-4094, 2003.
65. Barillari G., Sgadari C., Toschi E., Monini P., and **Ensoli B.** HIV protease inhibitors as new treatment options for Kaposi's sarcoma. Drug Res. Update, 6:173-181, 2003.
66. Sgadari C., Monini P., Barillari G. and **Ensoli B.** Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol., 4:537-547, 2003.

67. Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., Ciccozzi M., Collacchi B., Sabbatucci M., Cafaro A., Guzmán C.A., Borsetti A., Caputo A., Vardas E., Colvin M., Lukwya M., Rezza G., **Ensoli B.**, and the Tat Multicentric Study Group. Sequence conservation and antibody cross-recognition of the clade B human immunodeficiency virus (HIV) type 1 Tat Protein in HIV-1-Infected Italian, Ugandan and South Africans. J. Infect. Dis., 188:1171-1180, 2003.
68. Marsili G., Borsetti A., Sgarbanti M., Remoli A.L., Ridolfi B., Stellacci E., **Ensoli B.**, and Battistini A. On the role of interferon regulatory factors in HIV-1 replication. Ann. NY Acad. Sci., 1010:29-42, 2003.
69. Alessandri G., Fiorentini S., Licenziati S., Bonafede M., Monini P., **Ensoli B.**, and Caruso A. CD8(+)CD28(-) T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features. J. Interferon Cytokine Res., 23:523-531, 2003.
70. Savarino A., Bensi T., Chiocchetti A., Bottarel F., Mesturini R., Ferrero E., Colosso L., Deraglio S., Ortolan E., Buttò S., Cafaro A., Katada T., **Ensoli B.**, Malavasi F., and Dianzani U. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. FASEB J., 17:461-463, 2003.
71. Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M.J.M., Ten Haaf P.J.F., Niphuis H., Koornstra W., Bieler K., Koestler J., Morein B., Cafaro A., **Ensoli B.**, Wagner R., and Heeney J.L. Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. J. Virol., 78:3333-3342, 2004.
72. Franzese O, Comandini A, Adamo R, Sgadari C, **Ensoli B**, Bonmassar E. HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. Cell Death Differ., 11:782-784, 2004.
73. Cara A., Maggiorella M.T., Bona R., Sernicola L., Baroncelli S., Negri D.R.M., Leone P., Fagrouch Z., Heeney J., Titti F., Cafaro A., and **Ensoli B.** Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. Virology, 324:531-9, 2004.
74. Caputo A., Brocca-Cofano E., Castaldello A., Altavilla G., De Michele R., Marchisio M., Gavioli R., Rolen U., Chiarantini L., Cerasi A., Dominici S., Magnani M., Cafaro A., Sparnacci K., Laus M., Tondelli L., and **Ensoli B.** Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine, 22:2910-24, 2004.
75. Negri D.R.M., Buffa V., Leone P., Bona R., Borghi M., Carlini F., De Angelis F., Indraccolo S., **Ensoli B.**, Cara A. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J. Immunol. Methods, 291:153-163, 2004.

76. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., Cara A., Negri D.R.M., Buttò S., Fiorelli V., Tripiciano A., Scoglio A., Caputo A., Borsetti A., Ridolfi B., Bona R., ten Haaft P., Macchia I., Leone P., Pavone-Cossut M.R., Nappi F., Ciccozzi M., Heeney J., Titti F., Cafaro A., and **Ensoli B.** Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine, 22:3258-3269, 2004.
77. Ridolfi B., Titti F., Fulgenzi D., Maggiorella M.T., Tinari A., Superti F., Parolin C., **Ensoli B.**, and Borsetti A. Infection of a Simian B Cell Line by Human and Simian Immunodeficiency Viruses. AIDS Res. Hum. Retrov., 20:723-732, 2004.
78. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., Bonaccorsi A., Marastoni M., Micheletti F., Cafaro A., Rimessi P., Caputo A. and **Ensoli B.** HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J. Immunol., 173:3838-3843, 2004.
79. Sirianni M.C., Libi F., Campagna M., Scaramuzzi D., Monini P., and **Ensoli B.** Role of killer inhibitory receptors in human herpesvirus type 8 infection and KS development. In Monduzzi Eds., International Proceedings Division, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal (Canada), July 18 – July 23, 2004, pp. 257-259.
80. Caputo A., Gavioli R. and **Ensoli B.** Recent advances in the development of HIV-1 Tat-based vaccines. Curr. HIV Res., 2:357-376, 2004.
81. Monini P., Sgadari C., Toschi E., Barillari G., and **Ensoli B.** Antitumor effects of antiretroviral activity. Nat. Cancer Rev., 4:861-875, 2004.
82. Ferrantelli F., Cafaro A., and **Ensoli B.** Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr. Opin. Biotech., 15:543-56, 2004.
83. Sgarbanti M., Marsili G., Remoli A.L., Ridolfi B., Stellacci E., Borsetti A., **Ensoli B.**, Battistini A. Analysis of the signal transduction pathway leading to human immunodeficiency virus-1-induced interferon regulatory factor-1 upregulation. Ann. NY Acad. Sci., 1030:187-195, 2004.
84. **Ensoli B.** AIDS Vaccine Integrated Project (AVIP). BIOforum Europe (01/2005), pp 38-40, 2005.
85. **Ensoli B.**, Buttò S., and Fiorelli V. Il vaccino contro l'HIV e l'AIDS. Notiziario dell'Istituto Superiore di Sanità, 18:9-13, 2005.
86. Rezza G., Fiorelli V., Dorrucchi M., Ciccozzi M., Tripiciano A., Scoglio A., Collacchi B., Ruiz-Alvarez M., Giannetto C., Caputo A., Tomasoni L., Castelli F., Sciandra M., Sinicco A., Ensoli F., Buttò S., and **Ensoli B.** The Presence of Anti-Tat Antibodies Is Predictive of Long-Term Non-Progression to AIDS or Severe Immunodeficiency: Findings from a Cohort of HIV Seroconverters. J. Infect. Dis., 191:1321-1324, 2005.
87. Biassoni R., Fogli M., Cantoni C., Costa P., Conte R., Koopman G., Cafaro A., **Ensoli B.**, Moretta A., Moretta L., De Maria A. Molecular and functional characterization of NKG2D, NKp80, and NKG2C triggering NK cell receptors in rhesus and cynomolgus macaques: monitoring of NK cell function during simian HIV infection. J. Immunol. 1:174:5695-5705,

2005.

88. Sirianni M.C., Libi F., Campagna M., Rossi D., Capello D., Sciaranghella G., Carbone A., Simonelli C., Monini P., Gaidano G., and **Ensoli B.** Down-regulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. Br. J. Haematol., 130:92-95, 2005.
89. Zhao J., Voltan R., Peng B., Davis-Warren A., Kalyanaraman V.S., Alvord W.G., Aldrich K., Bernasconi D., Buttò S., Cafaro A., **Ensoli B.**, and Robert-Guroff M. Enhanced cellular immunity to SIV Gag following co-administration of Adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology, 342:1-12, 2005.
90. Sparnacci K., Laus M., Tondelli L., Bernardi C., Magnani L., Corticelli F., Marchisio M., **Ensoli B.**, Castaldello A., and Caputo A. Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins. J. Biomater. Sci. Polymer. Edn., 16:1557-1574, 2005.
91. **Ensoli B.** Introduction: rational vaccine strategies against AIDS. Microbes Infect., 7:1385, 2005.
92. **Ensoli B.** Rational vaccine strategies against AIDS: background and rationale. Microbes Infect., 7:1445-1452, 2005.
93. **Ensoli B.** Criteria for selection of HIV vaccine candidates-general principles. Microbes Infect., 7:1433-1435, 2005.
94. **Ensoli B.**, Cafaro A., Caputo A., Fiorelli V., Ensoli F., Gavioli R., Ferrantelli F., Cara A., Titti F., and Magnani M. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect., 7:1392-1399, 2005.
95. Ensoli F., Fiorelli V., Buttò S., Gavioli R., Caputo A., Monini P., Ferrantelli F., Titti F., Cafaro A., and **Ensoli B.** HIV/AIDS vaccine based on the native Tat protein: from basic science to clinical trials. Giornale Italiano di Malattie Infettive (Italian), Vol.11(4):151-155, 2005.
96. Borsutzky S., Ebensen T., Link C., Daniel Becker P., Fiorelli V., Cafaro A., **Ensoli B.**, and Guzmán C.A. Efficient systemic and mucosal responses against the HIV-1 Tat protein by Prime/Boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine, 24:2049-2056, 2006.
97. Garrafa E., Alessandri G., Benetti A., Turetta D., Corradi A., Cantoni A.M., Cervi E., Bonardelli S., Parati E., Giulini S.M., **Ensoli B.**, and Caruso A. Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils J. Cell. Physiol., 207:107-113, 2006.
98. Toschi E., Bacigalupo I., Strippoli R., Cereseto A., Falchi M., Chiozzini C., Nappi F., Sgadari C., Barillari G., Mainiero F., and **Ensoli B.** HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol. Biol. Cell, 17:1985-1994, 2006.

99. Remoli A.L., Marsili G., Pernotti E., Gallerani E., Ilari R., Nappi F., Cafaro A., **Ensoli B.**, Gavioli R., and Battistini A. Intracellular HIV-1 tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem. J., 396:371-380, 2006.
100. Buffa V., Negri D.R.M., Leone P., Bona R., Borghi M., Bacigalupo I., Carlei D., Sgadari C., **Ensoli B.**, and Cara A. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. J. Gen. Virol. 87:1625-1634, 2006.
101. Castaldello A., Brocca-Cofano E., Voltan R., Triulzi C., Altavilla G., Laus M., Sparnacci K., Balestri M., Tondelli L., Fortini C., Gavioli R., **Ensoli B.**, and Caputo A. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine, 24:5655-5669, 2006.
102. Pardini M., Giannoni F., Palma C., Iona E., Cafaro A., Brunori L., Rinaldi Monica, Fazio Vito, Laguardia M., Carbonella C., Magnani M., **Ensoli B.**, Fattorini L., and Cassone A. Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis. FEMS Microbiol. Lett., 262:210-215, 2006.
103. Simonelli C., Talamini R., Bearz A., Berretta M., Spazzapan S., Monini P., Sgadari C., Sartor I., **Ensoli B.**, and Tirelli U. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. Ann. Oncol., 17:1335-1336, 2006.
104. Sgadari C., Toschi E., Bacigalupo I., Sabbatucci M., Palladino C., Carlei D., Barillari G., and **Ensoli B.** Patogenesi del Sarcoma di Kaposi. In: Tumori ed Infezioni da HIV. Patogenesi e studi clinici del GICAT (Italian). Milano: Biomedica, pp. 15-26, 2006.
105. **Ensoli B.**, Fiorelli V., Longo O., Bellino S., Ensoli F., Tripiciano A., Scoglio A., Ruiz M., Collacchi B., Francavilla V., Lazzarin A., Tambussi G., Visintini R., Narciso P., D'Offizi G., Giulianelli M., Carta M., Di Carlo A., Palamara G., and Giuliani M. Prophylactic and therapeutic Phase I trials with the active Tat protein vaccine: results of the interim analysis. In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 79, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).
106. Cafaro A., Fanales-Belasio E., Moretti S., Fiorelli V., Pavone-Cossut M.R., Tripiciano A., Ferrantelli F., Olivieri E., Nappi F., Macchia I., Monini P., and **Ensoli B.** Native Tat preferentially enters dendritic cells inducine tumor necrosis factor- α mediated Th1-polarized maturation and immune responses in monkeys and humans. In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 83, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).
107. Titti F., Ferrantelli F., Olivieri E., Farcomeni S., Leone P., Macchia I., Maggiorella T., Borsetti A., Cafaro A., Srivastava I., Monini P., Barnett S., and **Ensoli B.** A novel HIV/AIDS vaccine based on the combination of HIV Tat and $\Delta V2$ -Env proteins: preclinical studies. In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 139, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29-

September 1, 2006).

108. Titti F., Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M.R., Macchia I., Farcomeni S., Tenner-Racz P.K., Racz P., and **Ensoli B.** Protective efficacy of multiprotein genetic vaccine in the SIV-macaca animal model. In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 188, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).
109. Titti F., Borsetti A., Baroncelli S., Maggiorella M.T., Moretti S., Sernicola L., Belli R., Ridolfi B., Catone S., Farcomeni S., Negri D.R.M., Cafaro A., and **Ensoli B.** Viral outcome of Simian-Human Immunodeficiency Virus SHIV-89.6P adapted in cynomolgus monkeys (SHIV-89.6 Pcy₂₄₃). In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 189, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).
110. Ensoli F., Fiorelli V., Tripiciano A., Scoglio A., Collacchi B., Ruiz-Alvarez M., Fazio A., Panicci G., Arancio A., Stivali F., Francavilla V., Longo O., Buttò S., Poli G., and **Ensoli B.** Anti-Tat humoral and cellular immunity in HIV-1 infected patients, including asymptomatic individuals and LTNP, aimed at identifying immune correlates of protection which are key to vaccine development. In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 140, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006)
111. **Ensoli B.**, Wahren B., Le Grand R., Gavioli R., Guzman C.A., Magnani M., Stanescu I., Erfle V., Barnett S., Gotch F., Vardas E., Glashoff R., Clerici M., Poli G., Holmes H., and Caputo A. AIDS Vaccine Integrated Project (AVIP): a consortium funded by the FP-6 EU program. In: Antiviral Ther. 11 (Suppl. 2), International Medical Press, pag. 157, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).
112. Goletti D., Macchia I., Leone P., Pace M., Sernicola L., Pavone-Cossut M.R., Maggiorella M.T., Cafaro A., **Ensoli B.**, and Titti F. Innate anti-viral immunity is associated with the protection elicited by the Simian Immunodeficiency Virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. Med. Sci. Monit., 12:BR330-340, 2006.
113. **Ensoli B.**, Fiorelli V., Ensoli F., Cafaro A., Titti F., Buttò S., Monini P., Magnani M., Caputo A., and Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS, 20:2245–2261, 2006.
114. Ferrantelli F., Buttò S., Cafaro A., Wahren B., and **Ensoli B.** Building Collaborative Networks for HIV/AIDS Vaccine Development: the AVIP experience. Springer Semin. Immun., 28:289-301, 2006.
115. Monini P., Toschi E., Sgadari C., Bacigalupo I., Palladino C., Carlei D., Barillari G. and **Ensoli B.** The use of HAART for biological tumour therapy. J. HIV Ther., 11:53-56, 2006.
116. Bozac A., Berto E., Vasquez F., Grandi P., Caputo A., Manservigi R., **Ensoli B.**, and Marconi P. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine, 24:7148-7158, 2006.

117. Buffa V., Negri D.R., Leone P., Borghi M., Bona R., Michelini Z., Compagnoni D., Sgadari C., **Ensoli B.**, and Cara A. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol., 19:690-701, 2006.
118. Demberg T., Florese R.H., Gomez-Roman V.R., Larsen K., Van Rompay K.K., Marthas M.L., Venzon D., Kalyanaraman V., Pal R., Barnett S.W., Cafaro A., **Ensoli B.**, and Robert-Guroff M. Non-neutralizing antibodies and vaccine-induced protection. Retrovirology, 3(Suppl 1):S26, 2006.
119. Titti F., Cafaro A., Ferrantelli F., Tripiciano A., Moretti S., Caputo A., Gavioli R., Ensoli F., Robert-Guroff M., Barnett S., and **Ensoli B.** Problems and emerging approaches in HIV/AIDS vaccine development. Exp. Opin. Emerg. Drugs, 12:23-48, 2007.
120. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Koriath-Schmitz B., Buzby A., Dombagoda D., Montefiori D.C., Letvin N.L., Cafaro A., **Ensoli B.**, and Robert-Guroff M. A replication-competent Ad-HIVtat and -HIVenv priming/1 Tat and Envelope protein boosting regimen elicits enhanced protective efficacy against SHIV89.6P challenge in rhesus macaques. J. Virol., 81:3414-3427, 2007.
121. Sirianni M.C., Campagna M., Scaramuzzi D., Carbonari M., Toschi E., Bacigalupo I., Monini P., and **Ensoli B.** Control of human herpes virus type 8-associated diseases by NK cells. Ann. N.Y. Acad. Sci. 1096:37-43, 2007.
122. Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M.R., Macchia I., Tenner-Racz K., Racz P., **Ensoli B.**, and Titti F. Multiprotein Genetic Vaccine in the SIV-Macaca animal model: a promising approach to generate sterilising immunity to HIV infection. J. Med. Primatol., 36:180-194, 2007.
123. Bråve A., Hinkula J., Cafaro a., Eriksson L.E., Srivastava I.K., Magnani M., **Ensoli B.**, Barnett S.W., Wahren B., Rollman E. Candidate HIV-1 gp140ΔV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine, 25:6882-6890, 2007.
124. Voltan R., Castaldello A., Brocca-Cofano E., Altavilla G., Caputo A., Laus M., Sparnacci K., **Ensoli B.**, Spaccasassi S., Ballestri M., and Tondelli L. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm. Res., 24:1870-1882, 2007.
125. Dehò L., Walwema R., Cappelletti A., Sukati H., Nsibandze D., Almaviva M., Buttò S., **Ensoli B.**, Galli M., and Balotta C. Characterization of human immunodeficiency virus type 1 from antiretroviral drug-naïve population in Swaziland. AIDS Res. Hum. Retrovir., in press.
126. Ridolfi B., Genovese D., Argentini C., Maggiorella M.T., Sernicola L., Buttò S., Titti F., Borsetti A., and **Ensoli B.** Tat protein vaccination of cynomolgus macaques influences SHIV-89.6p_{cy243} epitope variability. Virus Genes, in press.

127. Borsetti A., Baroncelli S., Maggiorella M.T., Bellino S., Moretti S., Sernicola L., Belli R., Ridolfi B., Farcomeni S., Negri D.R.M., Cafaro A., **Ensoli B.**, and Titti F. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch. Virol., in press.